Adial Pharmaceuticals Inc... (ADIL)
0.75
-0.04 (-4.46%)
At close: Mar 03, 2025, 3:59 PM
0.73
-2.19%
After-hours: Mar 03, 2025, 05:32 PM EST
Company Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.
Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.
The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders.
Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Adial Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Jul 27, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Cary John Claiborne MBA |
Contact Details
Address: 1180 Seminole Trail Charlottesville, Virginia United States | |
| Website | https://www.adialpharma.com |
Stock Details
| Ticker Symbol | ADIL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001513525 |
| CUSIP Number | 00688A106 |
| ISIN Number | US00688A2050 |
| Employer ID | 80-0667150 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Cary John Claiborne MBA | Chief Executive Officer, President & Director |
| John R. Martin J.D. | Chief Legal Officer |
| Tony Goodman | Chief Operating Officer & Director |
| Vinay Shah A.C.A., M.B.A. | Chief Financial Officer |
| Andrew Taubman | Vice President of Corporate Development |
| Dr. Brigette Robertson M.D. | Acting Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 25, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 08, 2025 | 8-K | Current Report |
| Dec 31, 2024 | 424B3 | Filing |
| Dec 20, 2024 | S-1 | Filing |
| Dec 18, 2024 | 8-K | Current Report |
| Dec 12, 2024 | S-8 | Filing |
| Dec 06, 2024 | 8-K | Current Report |
| Dec 05, 2024 | 4 | Filing |
| Nov 18, 2024 | 8-K | Current Report |